Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of AT13148 for advanced solid tumours
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a drug called AT13148 for solid tumours that had continued to grow despite other treatment. This is advanced cancer.
This trial was supported by Cancer Research UK.
More about this trial
AT13148 is a type of targeted cancer drug called a cancer growth blocker. It blocks signals that cancer cells use to divide and grow.
Researchers have tested this drug in the laboratory. This research showed that it can block these messages and stop cancer cells growing.
This is the first time people had AT13148.
The aims of the trial were to:
- find the best dose of AT13148
- learn more about the side effects of AT13148
- see how well it worked
- see what happened to the drug in the body (
- learn more about how AT13148 works and what it does to the body (
Summary of results
The trial team found the best dose of AT13148 to give. In a very few people, the cancer stayed the same. But AT13148 treatment didn’t shrink the cancer in anyone who took part.
This trial was open for people to join between 2012 and 2017. Researchers reported the results in 2018.
About this trial
pancreas bile duct
51 people had treatment. They had at least 1 dose of AT13148.
AT13148 is a capsule. People had this capsule 3 times a week. The first few people taking part had a low dose of AT13148. If they didn’t have any serious side effects, the next people had a higher dose. And so on, until the researchers found the best dose to give. This is called a dose escalation study.
People could have treatment for up to a year if it was working and the side effects weren’t too bad. But nobody had treatment for this long.
Researchers looked at the results of the dose escalation study. They found the best dose of AT13148 was 180mg. 14 people had this dose. There were too many side effects at the two highest doses that people had (240 mg and 300 mg). So, a lower dose of 180 mg was chosen as the best dose.
Researchers looked at how well AT13148 worked. To do this they measured the tumours with scans at the beginning of the trial and every 2 months. They included 18 people in this analysis. They found:
- in 3 people the cancer stayed the same (
- in 15 people the cancer got worse
AT13148 treatment didn’t shrink the cancer in anyone who took part.
The trial team took blood samples. They looked at what happened to AT13148 in the body. Five people had the highest dose of the drug. This was 300 mg. At this dose, lab tests showed that the drug worked as expected. But due to the side effects, it wasn’t a suitable dose to give to more people.
At the doses lower than 300 mg it wasn’t possible to block the cancer signals that the cancer used to divide and grow.
Low blood pressure was a common side effect. The researchers looked at tumour samples that some people gave. The results showed that the drug affected how the body regulated blood pressure. They didn’t know about this when they started the trial.
36 out of 51 people who had AT13148 reported side effects. The most common were:
- low blood pressure
- feeling sick
Other side effects included:
- loss of appetite
- being sick
10 people had serious side effects. These included:
- low blood pressure
- liver problems
- a decrease in a type of white blood cell called
- low oxygen in the blood
- lung inflammation (pneumonitis)
- feeling sick
- kidney problems
The trial team found the best dose of AT13148 to give. But it didn’t help to shrink the tumours in anyone who had treatment in this trial.
The trial has helped researchers learn more about:
- the side effects of AT13148
- how AT13148 works
- how it affects the body and what the body does to the drug
At the moment, the trial team are not planning to look at AT13148 in more trials.
Where this information comes from
We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Dr Udai Banerji
Cancer Research UK (Centre for Drug Development)
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
NIHR Clinical Research Network: Cancer
The Royal Marsden NHS Foundation Trust